Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMP-336B11 in advanced solid tumors
NCT03295942Phase 1Terminated
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Jul 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GITRL-Fc in solid tumor, sponsored by OncoMed Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose or Maximum Administered Dose at Day 29. Started Sep 2017; status: terminated.
02
Drugs
GITRL-Fc
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03295942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295942.